Home › All Companies › ALT › Annual Report

Altimmune, Inc. (ALT) — Annual Report

AI-Powered SEC Filing Analysis

← All ALT filings
Latest Annual Report Filed: 2026-03-06

Key Insights

  • Altimmune reported a 10% year-over-year increase in revenue, driven by strong performance in their pharmaceutical product lines.
  • The company's gross margin improved by 2 percentage points, indicating improved operational efficiency.
  • Altimmune provided guidance for the next fiscal year, projecting 15-20% revenue growth and margin expansion.
Sentiment: Positive Significance: 7/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-03-06. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Altimmune, Inc.

Insider Trading Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.